Vedanta Biosciences Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Vedanta Biosciences's estimated annual revenue is currently $13.5M per year.
- Vedanta Biosciences received $27.0M in venture funding in December 2018.
- Vedanta Biosciences's estimated revenue per employee is $155,000
- Vedanta Biosciences's total funding is $82.4M.
- Vedanta Biosciences has 87 Employees.
- Vedanta Biosciences grew their employee count by -8% last year.
- Vedanta Biosciences currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Cell Signaling ...||$89.4M||577||N/A||N/A||N/A|
What Is Vedanta Biosciences?
The trillions of microbes that call us home the human microbiome - perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival. Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta was co-founded by PureTech Health and a group of world renowned experts in immunology and microbiologykeywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Daniel Couto||Chief Operating Officer||Email Available|
|Bernat Olle||Chief Executive Officer||Email Available|
|David Crane||Sr. Qa Manager||Email Available|
|Scott Michonski||Senior Manager Of Process Development||Email Available|
|Jeffrey Grau||Director Of Facilities||Email Available|
|Jack Kyte||Senior Director Human Resources||Email Available|
|Aaron Bushold||QC Manager||Email Available|
|Marie Allen||Sr Director Quality|
|Jil Ulrich||Associate Director of CMC Operations||Email Available|
|Kris Ireland||Director Of Manufacturing||Email Available|
Vedanta Biosciences News
Human Microbiome Therapeutics Market 2019 Business Scenario – Enterome Bioscience, Rebiotix, Seres Therapeutics, Vedanta Biosciences.
... Second Genome, uBiome, Inc., Metabiomics Corp., Rebiotix, Inc., Vedanta Biosciences, Enterome, Biosciences, and Synthetic Biologics, Inc.
Top Players Profiled in this Report includes, Enterome Bioscience ... Second Genome Inc. (U.S.), Yakult (Japan), Vedanta BioSciences (U.S.), ...
Vedanta Biosciences Funding
Vedanta Biosciences Executive Hires
|2016-03-17||Bruce L Roberts||Chief Scientific Officer||Article|
|2016-04-15||Daniel E. Couto||SVP Development and Manufacturing||Article|